Shanghai, China – May 18, 2022 – VivaVision Biotech (Shanghai) Co., Ltd. (hereinafter referred to as "VivaVision Biotech") and Shanghai AceMab Co., Ltd. (hereinafter referred to as "AceMab") today announced the establishment of a strategic collaboration. The partnership will focus on the joint development of bispecific antibody therapeutics targeting retinal diseases.
VivaVision Biotech is an innovative ophthalmic drug discovery and development company. AceMab is a specialized service provider offering high-quality, one-stop therapeutic antibody discovery services based on its proprietary AceMouse™ transgenic mouse platform. Through this strategic collaboration, AceMab's advanced AceMouse™ common light chain bispecific antibody transgenic mouse platform will empower VivaVision Biotech in the development and advancement of bispecific antibodies, enabling the identification of optimal bispecific antibody candidate sequences. This collaboration aims to fulfill VivaVision Biotech's pioneering mission of delivering novel solutions for retinal diseases. The partnership will leverage the strengths of AceMab's bispecific antibody discovery platform to advance VivaVision's development of sustained-release molecules for retinal diseases, while also laying a solid foundation for subsequent process development. It is anticipated that through this in-depth collaboration, more patients suffering from wet age-related macular degeneration (wAMD) will benefit, and it holds the potential to treat over 60% of patients with diabetic macular edema (DME).
Dr. Jianliang Li, CEO of AceMab:
"We are deeply honored to be a core participant in VivaVision's retinal drug R&D process. AceMab's AceMouse™ mice and their derived common light chain strains possess antigen-specific immune responses comparable to wild-type BALB/c mice. We possess globally leading, unique technological expertise in the R&D of therapeutic monoclonal or bispecific antibodies against complex receptor targets, conserved protein targets, and GPCR targets. We believe the outcomes of this collaborative R&D will bring significant benefits to patients with AMD and DME."
Dr. Wang Shen, CEO of VivaVision Biotech:
"AMD and DME are major retinal diseases leading to vision loss in patients. Existing therapies, particularly for DME, often show limited efficacy, placing a tremendous economic and health burden on patients. With the acceleration of population aging and the rising number of diabetic patients, the population suffering from retinal diseases will continue to grow rapidly. Through our collaboration with AceMab, we aim to expedite the development of antibody therapeutics and provide retinal disease specialists with superior treatment options, ultimately benefiting more patients with retinal diseases."
